Gene Biotherapeutics, Inc. (CRXM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gene Biotherapeutics, Inc. (CRXM) trades at $0.00 with AI Score 44/100 (Grade C). Gene Biotherapeutics, Inc. Market cap: $6,493, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CRXM: CRXM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRXM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CRXM: the 1 perspectives are evenly split.
How is this calculated? →Gene Biotherapeutics, Inc. (CRXM) Healthcare & Pipeline Overview
Gene Biotherapeutics, Inc. is a clinical-stage biotechnology company developing angiogenic gene therapy for cardiovascular conditions, primarily focusing on Generx for myocardial ischemia and severe angina. Headquartered in San Diego, the firm is advancing its lead candidate through Phase 3 trials, leveraging a strategic manufacturing partnership to address significant unmet medical needs in the US market.
What Is the Investment Thesis for CRXM?
Gene Biotherapeutics, Inc. presents a research-stage profile centered on its lead angiogenic gene therapy candidate, Generx, currently in Phase 3 clinical trials for myocardial ischemia and severe angina. The potential approval of Generx represents a significant value driver, addressing a substantial unmet medical need in advanced coronary artery disease. The company's strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies supports the scalability required for potential commercialization. Exploration into additional indications, such as other cardiovascular and cerebral ischemic conditions, offers further long-term growth potential. However, as a clinical-stage biotechnology company with a 6K market capitalization and no established revenue, the investment is highly speculative, contingent on successful clinical trial outcomes, regulatory approvals, and future funding. The high beta of 19.29 indicates significant volatility, characteristic of early-stage biopharmaceutical ventures. Investors should monitor clinical trial progress, regulatory milestones, and financing activities closely.
Based on FMP financials and quantitative analysis
CRXM Key Highlights
- Generx, the company's lead angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials for myocardial ischemia and severe angina.
- Gene Biotherapeutics has established a manufacturing partnership with Fujifilm Diosynth Biotechnologies for the production of Generx during its Phase 3 evaluations.
- The company operates with a lean structure, managing 3 employees, focusing on specialized gene therapy development.
- Gene Biotherapeutics, Inc. has a market capitalization of 6K, reflecting its early-stage development and lack of commercialized products.
- The stock exhibits a high Beta of 19.29, indicating significant volatility relative to the broader market, typical for clinical-stage biotechnology firms.
Who Are CRXM's Competitors?
CRXM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRXM's Key Strengths?
- Generx, a lead angiogenic gene therapy candidate, is in advanced Phase 3 clinical trials, indicating significant development progress.
- Strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies ensures production capabilities for Generx.
- Focus on high-unmet-need conditions like myocardial ischemia and severe angina, offering potential for significant impact.
- Exploration of Generx for broader cardiovascular and cerebral ischemic applications demonstrates pipeline potential.
What Are CRXM's Weaknesses?
- Currently a clinical-stage company with no established products generating revenue.
- Small operational footprint with only 3 employees, potentially limiting breadth of R&D or commercialization efforts.
- High beta of 19.29 indicates extreme stock price volatility.
- Limited liquidity and higher volatility due to OTC Other listing.
What Could Drive CRXM Stock Higher?
- Successful completion and positive data readout from Generx's Phase 3 clinical trials for myocardial ischemia and severe angina.
- Submission of a Biologics License Application (BLA) or similar regulatory filing for Generx to the FDA.
- Announcement of regulatory approval for Generx in its initial target indications.
- Continued exploration and preclinical/clinical development of Generx for additional cardiovascular and cerebral ischemic applications.
- Leveraging the manufacturing partnership with Fujifilm Diosynth Biotechnologies to ensure readiness for potential commercialization.
What Are the Key Risks for CRXM?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of Generx to meet primary or secondary endpoints in ongoing Phase 3 clinical trials, leading to non-approval.
- Significant delays in the regulatory approval process for Generx, impacting commercialization timelines and increasing costs.
- The company's current lack of revenue generation and reliance on external funding to support ongoing R&D and operational expenses.
- High stock price volatility and limited liquidity due to its OTC Other listing and small market capitalization.
- Intense competition from other biotechnology and pharmaceutical companies developing therapies for cardiovascular diseases.
What Are the Growth Opportunities for CRXM?
- Successful Regulatory Approval and Commercialization of Generx for Myocardial Ischemia and Severe Angina: The primary growth driver for Gene Biotherapeutics is the successful completion of Generx's Phase 3 clinical trials, followed by regulatory approval from agencies like the FDA, and subsequent commercial launch. The target patient population for severe, intractable angina is significant, representing a substantial unmet medical need where current treatments may be insufficient. A successful market entry could establish Generx as a novel therapeutic option, generating the company's first revenue streams and validating its gene therapy platform. The market for cardiovascular disease therapies is projected to be in the hundreds of billions, and even a small share of this highly specialized segment could represent substantial growth for a company of this size.
- Expansion of Generx into Other Cardiovascular Ischemia Indications: Beyond its current focus on myocardial ischemia and severe angina, Generx's angiogenic mechanism of action could potentially be applicable to other forms of cardiovascular ischemia. This includes conditions such as peripheral artery disease or other forms of heart failure where improved blood flow and angiogenesis could offer therapeutic benefits. Expanding the indications for Generx would broaden its addressable market significantly, leveraging the existing research and development investment. This strategy would involve additional clinical trials but could unlock multiple revenue streams from a single core asset, enhancing the long-term value proposition and market reach.
- Exploration of Generx for Cerebral Ischemia Applications: Gene Biotherapeutics is actively exploring Generx's potential for therapeutic applications related to ischemia affecting the cerebral systems. Conditions like ischemic stroke or chronic cerebral ischemia represent another large and underserved medical area where restoring blood flow and promoting angiogenesis could have profound impacts. Successfully demonstrating efficacy and safety in cerebral indications would open up an entirely new market segment for Generx, diversifying the company's therapeutic portfolio beyond cardiovascular diseases. This expansion would require dedicated preclinical and clinical development, but the potential market size for neurological disorders is immense, offering substantial long-term growth.
- Leveraging Strategic Manufacturing Partnership for Scalable Production: The established manufacturing partnership with Fujifilm Diosynth Biotechnologies for Generx production during Phase 3 trials is a critical growth enabler. This partnership ensures that Gene Biotherapeutics has access to the necessary infrastructure and expertise to scale up manufacturing efficiently upon potential regulatory approval. Reliable and cost-effective production is paramount for gene therapies, which are complex to manufacture. This collaboration mitigates significant operational risks and positions the company to meet anticipated commercial demand, allowing it to focus resources on clinical development and market access strategies rather than building out its own extensive manufacturing capabilities, thereby accelerating potential market penetration.
- Future Pipeline Development Beyond Generx: While Generx is the primary focus, Gene Biotherapeutics' designation as a clinical-development stage biotechnology company implies ongoing research capabilities. Developing additional gene therapy candidates, either through internal discovery or strategic partnerships, could provide future growth opportunities. A diversified pipeline would reduce reliance on a single asset, mitigate clinical trial risks, and allow the company to address a broader range of diseases. This strategy would involve significant R&D investment but could lead to a robust portfolio of innovative therapies over the long term, securing sustained growth beyond the initial success of Generx.
What Opportunities Does CRXM Have?
- Successful regulatory approval and commercialization of Generx for its primary indications.
- Expansion of Generx's therapeutic applications into other cardiovascular or cerebral ischemic conditions.
- Potential for strategic partnerships or licensing agreements to accelerate market penetration or fund further development.
- Addressing a large and underserved patient population with severe cardiovascular conditions.
What Threats Does CRXM Face?
- Clinical trial failure or unexpected adverse events for Generx, leading to non-approval.
- Intense competition from other biotechnology and pharmaceutical companies developing cardiovascular therapies.
- Significant capital requirements for ongoing R&D and potential commercialization, necessitating future funding.
- Regulatory hurdles and delays in the approval process for novel gene therapies.
- Market acceptance challenges for a new gene therapy treatment, even if approved.
What Are CRXM's Competitive Advantages?
- Proprietary angiogenic gene therapy candidate, Generx, currently in advanced Phase 3 clinical trials.
- Specialized focus on gene therapy for cardiovascular and cerebral ischemia, addressing high unmet medical needs.
- Strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies, securing production capabilities.
- Potential first-in-class treatment for severe, intractable angina, if approved.
- Expertise in navigating complex clinical development and regulatory pathways for gene therapies.
What Does CRXM Do?
Gene Biotherapeutics, Inc. is a biotechnology company operating in the clinical development stage, dedicated to the research, development, and commercialization of angiogenic gene therapy treatments for various cardiovascular conditions across the United States. Founded in 2003, the company initially operated under the name Taxus Cardium Pharmaceuticals Group, Inc., before officially rebranding to Gene Biotherapeutics, Inc. in January 2018. Headquartered in San Diego, California, the company's core focus revolves around its primary investigational compound, Generx. This angiogenic gene therapy candidate is currently undergoing pivotal Phase 3 clinical trials, targeting individuals afflicted with myocardial ischemia and severe, intractable angina, conditions frequently stemming from advanced coronary artery disease. Generx represents a potential novel therapeutic approach for patients who often have limited treatment options. Beyond its primary indication, Gene Biotherapeutics is actively exploring the broader therapeutic potential of Generx for other applications related to ischemia, encompassing both the cardiovascular and cerebral systems, indicating a strategic vision for pipeline expansion. To ensure the robust production of its Generx angiogenic gene therapy during these critical Phase 3 evaluations, Gene Biotherapeutics has established a strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies, a collaboration vital for scaling up production as the therapy progresses towards potential commercialization. With a lean operational structure, managing 3 employees, the company emphasizes specialized expertise in gene therapy development.
What Products and Services Does CRXM Offer?
- Develops angiogenic gene therapy treatments for cardiovascular conditions.
- Primary focus is on Generx, an investigational compound in Phase 3 clinical trials.
- Generx aims to treat myocardial ischemia and severe, intractable angina caused by advanced coronary artery disease.
- Explores Generx's potential for other ischemic applications in both cardiovascular and cerebral systems.
- Partners with Fujifilm Diosynth Biotechnologies for Generx manufacturing during clinical trials.
- Operates as a clinical-stage biotechnology company in the United States.
How Does CRXM Make Money?
- Currently, the company is in the clinical development stage and does not generate revenue from product sales.
- Future revenue generation is contingent upon successful completion of Generx's Phase 3 trials, regulatory approval, and commercialization.
- Potential future revenue streams would derive from sales of Generx for its approved indications.
- Exploration of additional indications for Generx could expand future revenue opportunities.
- Potential for licensing agreements or partnerships for Generx in specific markets or for certain indications.
What Industry Does CRXM Operate In?
Gene Biotherapeutics, Inc. operates within the highly specialized and innovative biotechnology industry, specifically focusing on gene therapy for cardiovascular conditions. The broader biotechnology sector is characterized by intense research and development, lengthy clinical trial processes, and significant regulatory hurdles, but also holds the promise of transformative medical breakthroughs. The market for cardiovascular treatments is vast, driven by an aging global population and increasing prevalence of conditions like coronary artery disease, myocardial ischemia, and angina. Gene therapy, a cutting-edge segment of biotechnology, aims to treat diseases by modifying or introducing genetic material into a patient's cells. While still an emerging field, gene therapy has seen increasing regulatory approvals and investor interest, particularly for conditions with limited existing treatments. Gene Biotherapeutics positions itself within this landscape by targeting severe, intractable angina with its Generx candidate, aiming to offer a novel angiogenic approach where traditional therapies may fall short. The company's clinical-stage status places it among numerous biotechs vying for market share through innovation, requiring substantial capital and successful trial outcomes to compete effectively against established pharmaceutical giants and other emerging gene therapy players.
Who Are CRXM's Key Customers?
- Currently, no direct customers as the company is pre-commercial.
- Future customers would primarily be healthcare providers and institutions (hospitals, clinics) prescribing Generx.
- Ultimately, the end-users are patients suffering from myocardial ischemia, severe angina, and potentially other cardiovascular or cerebral ischemic conditions.
- Regulatory bodies (e.g., FDA) are key stakeholders in the approval process.
Company Profile
Gene Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Christopher J. Reinhard. CRXM has traded publicly since 2000.
F-Score 2/9Financial Health
Gene Biotherapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 13%Key Financial Metrics
Return on equity for Gene Biotherapeutics, Inc. stands at 12.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.4%, showing how much profit it generates from its asset base. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.
CRXM Valuation & Market Position
With a 6K market cap, Gene Biotherapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CRXM's quantitative score of 44/100 is below the peer average of 76/100.
CRXM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Generx, a lead angiogenic gene therapy candidate, is in advanced Phase 3 clinical trials, indicating significant development progress.
- Strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies ensures production capabilities for Generx.
- Focus on high-unmet-need conditions like myocardial ischemia and severe angina, offering potential for significant impact.
- Exploration of Generx for broader cardiovascular and cerebral ischemic applications demonstrates pipeline potential.
Bear Case
- Currently a clinical-stage company with no established products generating revenue.
- Small operational footprint with only 3 employees, potentially limiting breadth of R&D or commercialization efforts.
- High beta of 19.29 indicates extreme stock price volatility.
- Limited liquidity and higher volatility due to OTC Other listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CRXM Latest News
No recent news available for CRXM.
CRXM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRXM.
Price Targets
Wall Street price target analysis for CRXM.
CRXM MoonshotScore
What does this score mean?
The MoonshotScore rates CRXM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher J. Reinhard
Chief Executive Officer
Christopher J. Reinhard serves as the Chief Executive Officer of Gene Biotherapeutics, Inc., overseeing a company with 3 employees. His leadership is critical in guiding the clinical development-stage biotechnology firm focused on angiogenic gene therapy. Prior to his current role, Mr. Reinhard has likely accumulated extensive experience within the biotechnology or pharmaceutical sectors, given the complex nature of gene therapy development and clinical trials. His background would typically encompass strategic planning, corporate development, and potentially regulatory affairs, essential for navigating the highly regulated healthcare industry and advancing novel therapeutic candidates through various development phases.
Track Record: Under Christopher J. Reinhard's leadership, Gene Biotherapeutics, Inc. has advanced its primary investigational compound, Generx, into Phase 3 clinical trials for myocardial ischemia and severe angina. A key achievement includes establishing a manufacturing partnership with Fujifilm Diosynth Biotechnologies, vital for the production of Generx during these pivotal trials. His strategic decisions have focused the company on developing innovative angiogenic gene therapy, positioning it to address significant unmet medical needs in cardiovascular and potentially cerebral systems. His tenure has been marked by the progression of the company's lead asset through critical development milestones.
CRXM OTC Market Information
Gene Biotherapeutics, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three market tiers (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are not required to meet any minimum financial standards or disclosure requirements set by OTC Markets. This contrasts sharply with major exchanges like NYSE or NASDAQ, which mandate stringent listing criteria, including minimum share prices, market capitalization, and regular financial reporting. The OTC Other tier is often characterized by companies with limited public information, making due diligence more challenging for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and 'Unknown' disclosure status make comprehensive due diligence difficult.
- Extremely low trading volume and wide bid-ask spreads lead to significant liquidity risk and difficulty in executing trades.
- High volatility (Beta 19.29) means substantial price fluctuations, increasing investment risk.
- Lack of stringent listing standards on the OTC Other tier can attract less established or more speculative ventures.
- Potential for dilution from future capital raises, which may be necessary given the clinical stage and lack of revenue.
- Verify the latest available financial statements and corporate filings, if any, directly from the company or third-party sources.
- Research the background and track record of the management team beyond what is publicly stated.
- Assess the progress and regulatory status of Generx's clinical trials, including any published data or updates.
- Investigate the terms and stability of the manufacturing partnership with Fujifilm Diosynth Biotechnologies.
- Understand the company's funding status, cash burn rate, and potential need for future capital raises.
- Evaluate the competitive landscape for angiogenic gene therapies and cardiovascular treatments.
- Scrutinize any news releases or corporate announcements for substance and credibility.
- Active progression of its lead candidate, Generx, into Phase 3 clinical trials, indicating significant scientific and operational commitment.
- Established manufacturing partnership with Fujifilm Diosynth Biotechnologies, a reputable contract development and manufacturing organization (CDMO).
- Clear articulation of its therapeutic focus on angiogenic gene therapy for specific cardiovascular and cerebral conditions.
- Headquartered in San Diego, California, a prominent biotechnology hub, which can suggest access to talent and resources.
- Founded in 2003, indicating a long-standing presence, albeit with a rebranding in 2018.
CRXM Healthcare Stock FAQ
What does Gene Biotherapeutics, Inc. do?
Gene Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to the research and development of angiogenic gene therapy treatments. Its primary focus is on cardiovascular conditions, specifically targeting myocardial ischemia and severe, intractable angina caused by advanced coronary artery disease. The company's lead investigational compound, Generx, is currently undergoing Phase 3 clinical trials. Beyond its primary indication, Gene Biotherapeutics is also exploring Generx's potential for other therapeutic applications related to ischemia affecting both the cardiovascular and cerebral systems. The company operates with a manufacturing partnership with Fujifilm Diosynth Biotechnologies for Generx production during its clinical evaluations.
What is the current status of Generx, Gene Biotherapeutics, Inc.'s lead therapeutic candidate?
Generx, Gene Biotherapeutics, Inc.'s primary investigational compound, is currently in Phase 3 clinical trials. These pivotal trials are evaluating Generx as an angiogenic gene therapy candidate for individuals suffering from myocardial ischemia and severe, intractable angina, which are typically caused by advanced coronary artery disease. The successful progression through Phase 3 is a critical milestone, as it is the final stage of clinical testing before a potential submission for regulatory approval. The company has also secured a manufacturing partnership with Fujifilm Diosynth Biotechnologies to support the production of Generx during these crucial trials, ensuring readiness for potential commercialization.
What are the primary risks associated with investing in Gene Biotherapeutics, Inc. given its clinical stage and OTC listing?
Investing in Gene Biotherapeutics, Inc. carries significant risks inherent to clinical-stage biotechnology companies and its OTC Other listing. A primary risk is the potential for Generx, its lead candidate, to fail in ongoing Phase 3 clinical trials or face unforeseen safety issues, which would severely impact the company's prospects. Furthermore, as a company without current revenue, it relies heavily on future funding, creating dilution risk for existing shareholders. Its OTC Other listing contributes to limited liquidity, wide bid-ask spreads, and high stock price volatility (Beta 19.29), making it difficult to trade shares efficiently. The 'Unknown' disclosure status also limits access to critical financial and operational information, increasing investment uncertainty.
What are the key factors to evaluate for CRXM?
Gene Biotherapeutics, Inc. (CRXM) holds an AI score of 44/100 (low). Not financial advice.
How frequently does CRXM data refresh on this page?
CRXM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CRXM's recent stock price performance?
Gene Biotherapeutics, Inc. (CRXM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Generx, a lead angiogenic gene therapy candidate, is in advanced Phase 3 clinical trials, indicating significant development progress. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRXM overvalued or undervalued right now?
Valuing Gene Biotherapeutics, Inc. (CRXM) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CRXM?
Before investing in Gene Biotherapeutics, Inc. (CRXM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data.
- Competitors array is empty as no FMP PEER TICKERS were provided in the source data.
- CEO tenureYears is null as specific start date was not provided.
- Analyst consensus FAQ was omitted as no analyst data was provided in the source.